Tetanus: A Contemporary Approach to Diagnosis and Management

Dr Neeraj Manikath , claude.ai

Abstract

Despite widespread immunization programs, tetanus remains a significant cause of morbidity and mortality globally, particularly in resource-limited settings and among inadequately vaccinated populations. This review provides a comprehensive, evidence-based approach to the diagnosis and management of tetanus, emphasizing practical clinical pearls and contemporary therapeutic strategies relevant to internists and intensivists.

Introduction

Tetanus, caused by the neurotoxin tetanospasmin produced by Clostridium tetani, continues to challenge clinicians worldwide. While preventable through vaccination, the disease manifests in unimmunized or inadequately immunized individuals following contamination of wounds with bacterial spores. With a case fatality rate ranging from 10-70% depending on healthcare resources and disease severity, prompt recognition and aggressive management are paramount.

Pathophysiology: Understanding the Enemy

C. tetani spores germinate in anaerobic conditions, typically in contaminated wounds. The vegetative bacteria produce tetanospasmin, an exotoxin that undergoes retrograde axonal transport to the central nervous system. Once in the spinal cord and brainstem, tetanospasmin irreversibly binds to presynaptic terminals, blocking the release of inhibitory neurotransmitters (GABA and glycine). This disinhibition results in unopposed excitatory activity, causing the characteristic muscle rigidity and spasms.

Clinical Pearl: Tetanospasmin binding is irreversible. Recovery requires sprouting of new nerve terminals, explaining why improvement takes weeks despite antitoxin administration. Management is essentially supportive until neuronal regeneration occurs.

Clinical Presentation and Diagnosis

Generalized Tetanus (80% of cases)

The classic presentation begins with trismus (lockjaw) and risus sardonicus (sardonic smile due to facial muscle spasm). The disease progresses cephalocaudally with:

• Nuchal rigidity and dysphagia
• Truncal rigidity with opisthotonus
• Generalized spasms triggered by minimal stimuli
• Autonomic instability (later stages)

Oyster: The incubation period (typically 7-21 days) inversely correlates with prognosis. Shorter incubation periods indicate greater toxin production and predict severe disease. Similarly, a short "period of onset" (time from first symptom to first spasm) <48 hours suggests poor prognosis.

Other Forms

Localized tetanus presents with rigidity confined to muscles near the wound site. It may remain localized or progress to generalized disease.

Cephalic tetanus, following head wounds or otitis media, involves cranial nerves, particularly VII, and often progresses to generalized tetanus.

Neonatal tetanus results from umbilical stump contamination, typically presenting at 3-14 days of life with poor feeding, irritability, and rigidity.

Diagnostic Criteria

Diagnosis remains clinical. Laboratory confirmation is neither sensitive nor necessary. The classic clinical triad consists of:

1. Trismus with or without risus sardonicus
2. Muscle rigidity
3. Spasms without altered consciousness

Hack: Apply gentle pressure to the tongue depressor when examining the pharynx. In tetanus, reflex masseter spasm causes the patient to bite down rather than gag—the "spatula test" (positive likelihood ratio 3.8).

Severity Grading

The Ablett classification helps guide management:

• Grade I (Mild): Trismus, mild dysphagia, rigidity, no spasms
• Grade II (Moderate): Moderate trismus, dysphagia, rigidity, brief spasms
• Grade III (Severe): Severe rigidity, prolonged spasms, respiratory compromise
• Grade IV (Very Severe): Grade III plus severe autonomic dysfunction

Management: A Systematic Approach

Step 1: Immediate Resuscitation and Assessment (First Hour)

Airway and Breathing: Early intubation should be considered for Grade III-IV disease before laryngospasm or respiratory failure supervenes. Trismus may necessitate fiberoptic or surgical airway.

ICU Admission: All but Grade I tetanus requires intensive care monitoring. Even Grade I may progress rapidly and warrants close observation in a high-dependency unit.

Minimize Stimulation: Transfer the patient to a quiet, dimly lit room. All interventions should be performed gently and, when possible, under sedation.

Step 2: Neutralize Circulating Toxin (Within 4 Hours)

Human Tetanus Immune Globulin (HTIG): 3000-6000 IU intramuscularly, divided into multiple sites. Some experts advocate for a portion (500 IU) administered intrathecally, though evidence remains controversial.

Pearl: HTIG only neutralizes unbound circulating toxin. It cannot reverse symptoms caused by toxin already bound to neural tissue. Early administration is crucial, but delays should not preclude administration—circulating toxin may persist for weeks.

Equine Tetanus Antitoxin: If HTIG is unavailable, use 50,000-100,000 IU of equine antitoxin (10,000 IU IV, remainder IM) after testing for hypersensitivity. Premedicate with antihistamines and corticosteroids.

Step 3: Eradicate the Organism

Wound Debridement: Identify and surgically debride the wound to remove necrotic tissue and reduce bacterial load. This should be performed under adequate sedation/anesthesia.

Hack: No obvious wound is found in 15-25% of cases. Common occult sources include dental abscesses, chronic ulcers, injection drug use sites, and puerperal infections. Thorough examination including speculum examination in postpartum women is essential.

Antibiotics:

• First choice: Metronidazole 500 mg IV every 6-8 hours for 7-10 days (associated with lower mortality than penicillin in some studies)
• Alternative: Penicillin G 2-4 million units IV every 4-6 hours

Oyster: Penicillin, as a GABA antagonist, may theoretically worsen symptoms, making metronidazole the preferred agent.

Step 4: Control Spasms and Rigidity

Benzodiazepines: First-line therapy for muscle spasms and sedation.

• Diazepam: 10-40 mg IV every 2-8 hours, titrated to effect (may require 100-300 mg/day)
• Midazolam infusion: 0.1-0.4 mg/kg/hour for continuous control

Pearl: Adequate sedation is the cornerstone of management. The goal is to prevent spasms while maintaining consciousness if possible, though deep sedation or even pharmacological paralysis may be necessary in severe cases.

Adjunctive Agents:

• Baclofen: Intrathecal baclofen (2000 μg bolus followed by 50-200 μg/hour) acts as a GABA agonist. Particularly useful when benzodiazepine requirements are excessive.
• Magnesium sulfate: 5 g IV loading dose, then 2-3 g/hour infusion. Reduces catecholamine release, prevents spasms, and blunts autonomic dysfunction. Target serum levels 2-4 mmol/L (4-8 mg/dL).
• Propofol: For refractory spasms requiring deep sedation
• Dantrolene: 1-2 mg/kg IV every 6 hours if other measures fail

Hack: Magnesium is your friend for autonomic instability. It's safer than multiple sympatholytics and provides additional muscle relaxation. Monitor deep tendon reflexes—loss of reflexes precedes respiratory depression.

Step 5: Neuromuscular Blockade (When Conservative Measures Fail)

When spasms cannot be controlled with sedatives:

• Vecuronium or rocuronium infusions
• Requires mechanical ventilation
• Continue sedation—paralysis without sedation is inhumane
• Consider daily interruption to assess improvement

Duration: Often required for 3-6 weeks until new nerve terminals sprout

Step 6: Manage Autonomic Dysfunction (Typically Week 2-3)

Autonomic instability manifests as:

• Hypertension alternating with hypotension
• Tachycardia/bradycardia
• Hyperpyrexia
• Profuse sweating
• Arrhythmias

Management Approach:

• Magnesium sulfate: First-line therapy
• Morphine: 5-20 mg/hour infusion (sympatholytic effect)
• Dexmedetomidine: 0.2-0.7 μg/kg/hour (α2-agonist with minimal respiratory depression)
• Avoid β-blockers: Associated with sudden death, possibly due to unopposed α-stimulation

Oyster: Autonomic dysfunction is the leading cause of death in adequately resourced settings. Lability is the hallmark—aggressive treatment of hypertension can precipitate cardiovascular collapse.

Step 7: Supportive Care

Nutrition: High caloric requirements (3000-4000 kcal/day) due to constant muscle activity. Early enteral nutrition via nasogastric tube if not intubated; otherwise, nasojejunal or parenteral nutrition.

Thromboprophylaxis: High risk due to immobility. Use pharmacological prophylaxis unless contraindicated.

Pressure Ulcer Prevention: Meticulous skin care given prolonged immobilization

Physiotherapy: Passive range of motion initially; active rehabilitation during recovery

Bladder Care: Indwelling catheter during acute phase

Step 8: Active Immunization

Critical Pearl: Natural infection does not confer immunity. Administer tetanus toxoid (Td or Tdap) at a site distant from HTIG administration during hospitalization (after one week to avoid interference). Complete the three-dose primary series (0, 4-8 weeks, 6-12 months).

Complications and Their Management

Respiratory Complications

• Aspiration pneumonia (common)
• Ventilator-associated pneumonia
• Pulmonary embolism
• Respiratory failure from laryngospasm or diaphragmatic spasm

Cardiovascular Complications

• Arrhythmias (may be fatal)
• Myocardial infarction from catecholamine surge
• Cardiac arrest

Other Complications

• Vertebral/long bone fractures from violent spasms
• Rhabdomyolysis
• Ileus
• Nosocomial infections (given prolonged ICU stay)

Prognosis

Mortality remains 10-20% in developed countries but exceeds 50% in resource-limited settings. Poor prognostic indicators include:

• Short incubation period (<7 days)
• Short period of onset (<48 hours)
• High Ablett grade
• Extremes of age
• Autonomic instability
• Delayed presentation

Recovery is gradual, with spasms resolving over 2-4 weeks and rigidity over 4-6 weeks. Complete neurological recovery is typical if the patient survives, though mild stiffness may persist for months.

Prevention

Post-exposure Prophylaxis depends on wound characteristics and immunization status:

Clean, Minor Wounds:

• Td if >10 years since last dose
• Complete primary series if unvaccinated

All Other Wounds:

• Td if >5 years since last dose
• Td + HTIG 250 IU if inadequately immunized (<3 doses or unknown status)

Hack: When immunization history is uncertain (common in immigrants and elderly patients), assume inadequate immunity and provide both Td and HTIG for high-risk wounds.

Conclusion

Tetanus management demands meticulous attention to detail, aggressive supportive care, and patience. Success requires neutralizing toxin, eliminating bacteria, controlling symptoms, supporting vital functions, and managing complications. Despite modern intensive care, outcomes depend significantly on disease severity at presentation, emphasizing the continued importance of prevention through universal immunization. Remember: the patient with tetanus has weeks of sprouting new nerve terminals ahead—our role is to support them safely through this journey.

References

1. Thwaites CL, Yen LM. Tetanus. Lancet. 2019;393(10181):1657-1668.

2. Rodrigo C, Fernando D, Rajapakse S. Pharmacological management of tetanus: an evidence-based review. Crit Care. 2014;18(2):217.

3. Yen LM, Thwaites CL. Tetanus. Lancet. 2019;393(10181):1657-1668.

4. Schiavo G, Matteoli M, Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev. 2000;80(2):717-766.

5. Thwaites CL, Yen LM, Loan HT, et al. Magnesium sulphate for treatment of severe tetanus: a randomised controlled trial. Lancet. 2006;368(9545):1436-1443.

6. Thwaites CL, Yen LM, Glover C, et al. Predicting the clinical outcome of tetanus: the tetanus severity score. Trop Med Int Health. 2006;11(3):279-287.

7. Bunch TJ, Thalji MK, Pellikka PA, Aksamit TR. Respiratory failure in tetanus: case report and review of a 25-year experience. Chest. 2002;122(4):1488-1492.

8. Brauner JS, Vieira SR, Bleck TP. Changes in severe accidental tetanus mortality in the ICU during two decades in Brazil. Intensive Care Med. 2002;28(7):930-935.

9. Centers for Disease Control and Prevention. Tetanus surveillance—United States, 2001-2008. MMWR Morb Mortal Wkly Rep. 2011;60(12):365-369.

10. Gibson K, Bonaventure Uwineza J, Kiviri W, Parlow J. Tetanus in developing countries: a case series and review. Can J Anaesth. 2009;56(4):307-315.